Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY mcarthuh@mskcc.org.
Heather L
HL
McArthur
Memorial Sloan Kettering Cancer Center, New York, NY.
Patrick G
PG
Morris
Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.
Clifford A
CA
Hudis
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000737:chemistry* / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*
D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases